Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

Bausch & Lomb Pharmaceutical, Inc. · Predicate Candidate Screening

6 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

87 daysmedian FDA review time
448 days90th percentile
6clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K884962ADDIT. INDICATIONS FOR BIO-COR EXT COLLAGEN CORNEABausch & Lomb Pharmaceutical, Inc.1990-02-094480
K884960ADDIT. INDICATION FOR FYODOROV COLLAGEN CORNEALBausch & Lomb Pharmaceutical, Inc.1989-02-13870
K884961ADDIT. INDICATIONS FOR BIO-COR II COLLAGEN CORNEALBausch & Lomb Pharmaceutical, Inc.1989-02-13870
K884364LABELING CHANGES TO BIO-COR EXT COLLANGEN CORNEALBausch & Lomb Pharmaceutical, Inc.1988-11-29400
K884363LABELING CHANGES TO BIO-COR II COLLANGEN CORNEALBausch & Lomb Pharmaceutical, Inc.1988-11-29400
K884362LABELING CHANGES TO FYODOROV COLLAGEN CORNEAL SHLDBausch & Lomb Pharmaceutical, Inc.1988-11-29400

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams: atlasbyauro.com/fda